Cyclooxygenase-2 as a therapeutic target

Inflammation Research

Volumn 47, Issue SUPPL. 2, 1998, Pages

  Mitchell, J A ^a   Evans, T W ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Anti inflammatory; Cardiovascular disease; Cox 2 inhibition; Therapeutic effects

Indexed keywords

CYCLOOXYGENASE 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTAGLANDIN;

CELL ADHESION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM; HOMEOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; SMOOTH MUSCLE;

EID: 0031756822     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050287     Document Type: Conference Paper

References (22)

1. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms PG endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263: 663-5.
2. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 1976;92:181-7.
3. Sneddon JM, Vane JR. Endothelial derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci USA 1988;85:2800-4.
4. Willis AL, Smith DL, Vigo C. Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids. Prog Lipid Res 1986;25:645-66.
5. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 1994;14: 1021-31.
6. Bishop-Bailey D, Pepper JR, Haddad EB, Newton R, Larkin SW, Mitchell JA. Induction of cyclo-oxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol 1997;17:1644-8.
7. Jourdan K, Mitchell JA, Evans TW. Release of isoprostanes by human pulmonary artery in organ culture by a cyclo-oxygenase and nitric oxide synthase dependent mechanism. Biochem Biophys Res Commun 1997;120:1280-5.
8. Bishop-Bailey D, Pepper JR, Larkin S, Evans TW, Mitchell JA. Differential induction of cyclo-oxygenase-2 in human arterial and venous smooth muscle cells: Role of endogenous prostanoids. 1997;122:19P.
9. Belvisi MG, Saunders MA, Hirst SJ, Haddad EB, Yacoub MH, Barnes PJ, et al. Induction of cyclooxygenase by cytokines in cultured human airway smooth muscle cells: Novel inflammatory role of this cell type. Br J Pharmacol 1996;120:910-6
10. Ross R. Atherosclerosis: A defense mechanism gone awry. Am J Pathol 1993;143:987-1002.
11. Mitchell JA, Larkin SW, Williams TJ. Cyclo-oxygenase-2: Regulation and relevance in inflammation. Biochem Pharmacol 1995;50:1535-42.
12. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
13. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclo-oxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-7.
14. Bishop-Bailey D, Pepper JR, Larkin S, Evans T, Mitchell JA. Interleukin-1β induces anti-proliferative prostanoids via cyclo-oxygenase-2 in human saphenous vein and internal mammary artery cells. Br J Pharmacol 1997;122:20P.
15. Bornfeldt KE, Campbell JS, Koyama H, Argast GM, Leslie CC, Raines EW, et al. The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets. J Clin Invest 1997;100:875-85.
16. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996;87:2095-147.
17. Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of functional longevity by inflammatory mediators. J Leukoc Biol 1993;54:283-8.
18. Mitchell JA, Bishop-Bailey D, Evans TW, Giembycz MA, Belvisi MG, Chivers S, et al. Role of cyclo-oxygenase-2 in the suppression of GMCSF release by cultures of human arterial and venous smooth muscle cells. Br J Pharmacol 1998;123:74P.
19. Saunders M, Mitchell JA, Seldon PM, Yacoub MH, Barnes PJ, Giembycz MA, et al. Release of granulocyte-macrophage colony stimulating factor (GMCSF) by human airway smooth muscle (HASM) cells in culture. Br J Pharmacol 1997;120:545-6.
20. Libby P, Li H. Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J Clin Invest 1993; 92:538-9.
21. Bishop-Bailey D, Burke-Gaffney A, Hellewell PG, Evans T, et al. Interleukin (IL)-1β-induced cyclo-oxygenase-2 activity inhibits ICAM-1 and VCAM-1 expression on saphenous vein smooth muscle cells. Br J Pharmacol 1997;122:21P.
22. Cirino G, Saunders M, Belvisi MG, Jourdan KB, Evans TW, Copponi A, et al. Relative potency of different nonsteroidal antiinflammatory drugs as inhibitors of purified cyclo-oxygenase-1 and cyclo-oxygenase-2. Br J Pharmacol 1998;in press.